ImmunityBio Inc. (NASDAQ:IBRX) saw its share price bounce by 9.94 p.c on Tuesday to end at $9.29 apiece following a high-profile assembly between its founder, Dr. Patrick Soon-Shiong, and Turkish President Recep Tayyip Erdogan, fueling optimism around the listed firm’s deliberate growth into Turkey.
The Turkish authorities posted a photograph of Erdogan and Soon-Shiong on Tuesday, which the latter reposted along with the caption: “Under his leadership, Turkey will be the center of excellence for patients with cancer in the region.”
While no further particulars were disclosed, the assembly sparked shopping for among traders on confidence that its deliberate growth in Turkey is making progress.
Photo by Tima Miroshnichenko on Pexels
Expansion to 34 Countries
It can be recalled that ImmunityBio Inc. (NASDAQ:IBRX) sought the approval of numerous nations and areas for the sale and advertising of Anktiva—an FDA-approved immunotherapy medicine to deal with particular sorts of non-muscle invasive bladder cancer.
So far, the drug has been accepted in 34 nations, including the US, the UK, Saudi Arabia, Macau, and European nations, raising prospects for further income growth.
To support the initiative, ImmunityBio Inc. has efficiently raised $100 million in recent funds, of which $75 million was drawn from a non-dilutive financing from Oberland Capital, while another $25 million was raised from a debt-to-share conversion by Nant Capital LLC, a company affiliated with Soon-Shiong.
Anktiva Propels Q2 Profits
Anktiva was owed for ImmunityBio Inc.’s (NASDAQ:IBRX) stellar income efficiency in the second quarter of the yr, having practically doubled last yr’s figures.
During the quarter, whole revenues ended at $51.24 million, marking a bounce of 94 p.c from the $26.4 million in the same period last yr.
Net loss, however, widened by 148 p.c to $230.39 million from $ 92.57 million year-on-year amid larger prices and loss before income taxes and non-controlling pursuits.
Strong Hedge Fund Conviction
Institutional traders remained bullish for ImmunityBio Inc. (NASDAQ:IBRX) in the second quarter of the yr, as evidenced by the surge in their dedicated capital.
Data from Insider Monkey confirmed that during the period, 27 hedge funds held positions in the stock, up from 25 in the earlier quarter.
More notably, their mixed holdings climbed by 62.6 p.c to $314.9 million from $193.7 million quarter-on-quarter
While we acknowledge the potential of IBRX as an investment, we believe certain AI shares offer higher upside potential and carry less draw back risk. If you’re trying for an extraordinarily undervalued AI stock that also stands to benefit considerably from Trump-era tariffs and the onshoring pattern, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.